Tango Therapeutics, Inc. (TNGX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−23.0x

Market Cap

$3.80B

MomentumView details →

1D Return

−1.10%

YTD Return

+153.77%

RSI (14)

35.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−23.0x

Market Cap

$3.80B

RSI (14)

35.4

MomentumView details →

1D Return

−1.10%

YTD Return

+153.77%

SummaryUpdated Jun 1, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in September 2020 through a special purpose acquisition company (SPAC) merger. Tango focuses on discovering and developing targeted cancer therapies using a precision medicine approach called synthetic lethality, where drugs are designed to selectively kill cancer cells with specific genetic vulnerabilities while sparing healthy cells.

Ask drillr about Tango Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

98.25%

Net Margin

−229.92%

EBITDA Margin

−227.25%

ROE (TTM)

−12.08%

ROA (TTM)

−11.52%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

+121.47%

EPS YoY

+35.61%

FCF YoY

+3.28%

Revenue CAGR 3Y

+35.89%

EPS CAGR 3Y

+26.89%

EBITDA YoY

+18.45%

EarningsView details →

EPS (Actual)

−$0.37

EPS Surprise

−16.64%

Beats (12Q)

3/12

Next Q EPS Est

−$0.35

Avg Surprise (4Q)

298.05%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

50.82x

Quick Ratio

50.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

53.81M

Net Income (TTM)

−123.72M

Op. CF (TTM)

−143.90M

Next earningsNov 3, 2026 →

Latest newsMore news →

Tango Therapeutics reported Q2 2026 financial results with zero revenue, a net loss of $55.3 million, and diluted EPS of -$0.37, while highlighting a 92% objective response rate for vopimetostat plus daraxonrasib and a 90% six-month progression-free survival rate.25d ago

Tango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.29d ago

Similar companies

Amylyx Pharmaceuticals, Inc.AMLX Shanghai Haohai Biological Technology Co., Ltd.06826.HK Arcus Biosciences, Inc.RCUS Tarsus Pharmaceuticals, Inc.TARS IDEAYA Biosciences, Inc.IDYA Catalyst Pharmaceuticals, Inc.CPRX Find similar companies →

Latest newsMore news →

Tango Therapeutics reported Q2 2026 financial results with zero revenue, a net loss of $55.3 million, and diluted EPS of -$0.37, while highlighting a 92% objective response rate for vopimetostat plus daraxonrasib and a 90% six-month progression-free survival rate.25d ago Tango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.29d ago